Status:
TERMINATED
Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Type1diabetes
Eligibility:
All Genders
3-5 years
Phase:
NA
Brief Summary
Eighteen preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to addres...
Detailed Description
The invesigators propose to deliver a structured multidisciplinary family-centered intervention over a 3-day weekend. The intervention will be based at a regional camp. The proposed camp encounters ai...
Eligibility Criteria
Inclusion
- Age 3-5.5 years old (+/- 2 months) at the date of camp session they are eligible to join.
- Child and Parents fluent in English
- Type 1 diabetes mellitus diagnosed for at least 10 months previous to date of first camp they are eligible to join.
- Taking insulin
- Custodial parent or guardian (preferable both parents or guardians) willing to attend both session of camp and the activities scheduled for them.
- Parent or guardian must sign consent before any study procedures are performed.
Exclusion
- Neonatal diabetes (diagnosis in the first 3 months of life) or documented Monogenic Diabetes of Youth; i.e., a likely genetic form of diabetes rather than an autoimmune etiology.
- Post-surgical diabetes (e.g., pancreatectomy for congenital hyperinsulinism). Such patients often cannot secrete glucagon, leading to a particularly severe inability to defend against hypoglycemia.
- Other severe chronic disease (e.g., cancer, cystic fibrosis) which in the judgment of the investigator is likely to significantly affect glycemic control.
- Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but the investigators will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible.
- Patients with hypothyroidism or hyperthyroidism must be clinically euthyroid and have free T4 and thyroid stimulating hormone within age-appropriate reference ranges at last medically indicated testing. Patients with out of range values may be retested after medication dose adjustment.
- Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with group activities.
- Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with group activities.
- Celiac disease is not an exclusion criterion.
Key Trial Info
Start Date :
August 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04279587
Start Date
August 19 2019
End Date
February 13 2023
Last Update
August 26 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Perrin C White
Dallas, Texas, United States, 75230
2
Children's Medical Center
Dallas, Texas, United States, 75235